Low activity of plasminogen activator: A common feature of non- iatrogenic comorbidities of schizophrenia

CNS and Neurological Disorders - Drug Targets

Volumn 14, Issue 3, 2015, Pages 325-330

  Hoirisch Clapauch, Silvia ^a   Nardi, Antonio E ^b  

^a MINISTÉRIO DA SAÚDE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Comorbidity; Drug na ve; Medication na ve; Metabolism; Plasminogen activator; Schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTROPHIN; PLASMINOGEN ACTIVATOR; UROKINASE;

ALCOHOLISM; ARTICLE; AUTOIMMUNE DISEASE; CANCER RISK; COMORBIDITY; DRUG ABUSE; ENZYME ACTIVITY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERINSULINEMIA; IATROGENIC DISEASE; INFLAMMATION; MORTALITY; QUALITY OF LIFE; REPRODUCTION; RISK FACTOR; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SUBSTANCE ABUSE; THROMBOEMBOLISM; THROMBOSIS; TOBACCO USE; COMPLICATION; METABOLISM;

COMORBIDITY; HUMANS; PLASMINOGEN ACTIVATORS; SCHIZOPHRENIA;

EID: 84929254667     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527314666150225142705     Document Type: Article

References (77)

1. Hoirisch-Clapauch S, Nardi AE. Psychiatric remission with warfarin: Should psychosis be addressed as plasminogen activator imbalance? Med Hypotheses 2013; 80: 137-41.
2. Benarroch EE. Tissue plasminogen activator: beyond thrombolysis. Neurology 2007; 69: 799-802.
3. Melchor JP, Strickland S. Tissue plasminogen activator in central nervous system: physiology and pathology. Thromb Haemost 2005; 93: 655-60.
4. Samson AL, Medcalf R. Tissue-type plasminogen activator: a multifaceted modulator of neurotransmission and synaptic plasticity. Neuron 2006; 50: 673-8.
5. Velakoulis D, Wood SJ, Wong MT, et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: A magnetic resonance imaging study of chronic schizophrenia, firstepisode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry 2006; 63: 139-49.
6. Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat Rev Neurosci 2005; 6: 603-14.
7. Haile WB, Wu J, Echeverry R, Wu F, An J, Yepes M. Tissue-type plasminogen activator has a neuroprotective effect in the ischemic brain mediated by neuronal TNF-α. J Cereb Blood Flow Metab 2011; 32: 57-69.
8. Hoirisch-Clapauch S, Nardi AE. Markers of low activity of tissue plasminogen activator/plasmin are prevalent in schizophrenia patients. Schizophr Res 2014; 159: 118-23.
9. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 4: 1123-31.
10. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiat Scan 2007; 116: 317-33.
11. Beary M, Hodgson R, Wildgust HJ. A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: clinical and research implications. J Psychopharmacol 2012; 26: 52-61.
12. Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ 2010; 341: c4245.
13. Masopust J, Maly R, Andrys C, Valis M, Bazant J, Hosak, L. Markers of thrombogenesis are activated in unmedicated patients with acute psychosis: a matched case control study. BMC Psychiatry 2011; 11: 2.
14. Phutane VH, Tek C, Chwastiak L, et al. Cardiovascular risk in a first-episode psychosis sample: a 'critical period' for prevention? Schizophr Res 2011; 127: 257-61.
15. Vancampfort D, Wampers M, Mitchell AJ, et al. A meta-analysis of cardio-metabolic abnormalities in drug naive, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 2013; 12: 240-50.
16. Ziedonis D, Nickou C. Substance abuse in patients with schizophrenia. In: Hwang MY, Bermanzohn PC, Eds. Schizophrenia and comorbid conditions: Diagnosis and treatment. American Psychiatric Publications; 2001; pp. 187-222.
17. Khantzian EJ. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry 1997; 4: 231-44.
18. Kumari V, Postma P. Nicotine use in schizophrenia: the selfmedication hypotheses. Neurosci Biobehav Rev 2005; 29: 1021-34.
19. Archie S, Rush BR, Akhtar-Danesh N, Malla A, Roy P, Zipursky RB. Substance use and abuse in first-episode psychosis: prevalence before and after early intervention. Schizophr Bull 2007; 33: 1354- 63.
20. Ramer R, Rohde A, Merkord J, Rohde H, Hinz B. Decrease of plasminogen activator inhibitor-1 may contribute to the antiinvasive action of cannabidiol on human lung cancer cells. Pharm Res 2010; 27: 2162-74.
21. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 23: 35-45.
22. Bahi A, Dreyer JL. Overexpression of plasminogen activators in the nucleus accumbens enhances cocaine-, amphetamine-and morphine-induced reward and behavioral sensitization. Genes Brain Behav 2008; 7: 244-56.
23. Niwa M, Yan Y, Nabeshima T. Genes and molecules that can potentiate or attenuate psychostimulant dependence: relevance of data from animal models to human addiction. Ann NY Acad Sci 2008; 1141: 76-95.
24. Maiya R, Zhou Y, Norris EH, Kreek MJ, Strickland S. Tissue plasminogen activator modulates the cellular and behavioral response to cocaine. Proc Natl Acad Sci USA 2009; 106: 1983-8.
25. Nagai T, Ito M, Nakamichi N, et al. The rewards of nicotine: regulation by tissue plasminogen activator-plasmin system through protease activated receptor-1. J Neurosci 2006; 26: 12374-83.
26. Takashima H, Matsumoto T, Nakae I, Yamane T, Horie M. Cigarette smoking impairs bradykinin-stimulated tissue plasminogen activator release in human coronary circulation. Thromb Res 2007; 120: 791-6.
27. Drake RE, Mueser KT. Co-occurring alcohol use disorder and schizophrenia. Alcohol Res Health 2002; 26: 99-102.
28. Mukamal KJ, Jadhav PP, D'Agostino RB, et al. Alcohol consumption and hemostatic factors. Analysis of the Framingham Offspring Cohort. Circulation 2001; 104: 1367-73.
29. Festa A, D'Agostino R Jr, Mykkanen L, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscl Thromb Vasc Biol 1999; 19: 562-8.
30. Zhu JY, Pang ZJ, Yu YH. Regulation of trophoblast invasion: the role of matrix metalloproteinases. Rev Obstet Gynecol 2012; 5: e137-43.
31. Charnock-Jones DS, Kaufmann P, Mayhew TM. Aspects of human fetoplacental vasculogenesis and angiogenesis. I. Molecular regulation. Placenta 2004; 25: 103-13.
32. Sacker A, Done DJ, Crow TJ. Obstetric complications in children born to parents with schizophrenia: a meta-analysis of case-control studies. Psychol Med 1996; 26: 279-88.
33. Lin HC, Chen IJ, Chen YH, Lee HC, Wu FJ. Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference? Schizophr Res 2010; 116: 55-60.
34. Rieder RO, Rosenthal D, Wender P. The offspring of schizophrenics: fetal and neonatal deaths. Arch Gen Psychiatry 1975; 32: 200-11.
35. Nilsson E, Lichtenstein P, Cnattingius S, Murray RM, Hultman CM. Women with schizophrenia: Pregnancy outcome and infant death among their offspring. Schizophr Res 2002; 58: 221-9.
36. Jablensky AV, Morgan V, Zubrick SR, Bower C, Yellachich LA. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry 2005; 162: 79-91.
37. Vigod SN, Kurdyak PA, Dennis CL, et al. Maternal and newborn outcomes among women with schizophrenia: a retrospective population-based cohort study. BJOG 2014; 121: 566-74.
38. Bennedsen BE, Mortensen PB, Olesen AV, Henriksen TB, Frydenberg M. Obstetric complications in women with schizophrenia. Schizophr Res 2001; 47: 167-75.
39. Marcoux S, Brisson J, Fabia J. The effect of cigarette smoking on the risk of preeclampsia and gestational hypertension. Am J Epidemiol 1989; 130: 950-7.
40. Matevosyan NR. Schizophrenia and Stein-Leventhal syndrome: comorbidity features. Arch Gynecol Obstet 2011; 284: 1035-41.
41. Malik P, Kemmler G, Hummer M, et al. Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial. J Clin Psychopharmacol 2011; 31: 274-80.
42. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998; 274: H1054-8.
43. Mortensen PB, Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 1993; 163: 183-9.
44. Cohen ME, Dembling B, Schorling JB. The association between schizophrenia and cancer: a population-based mortality study. Schizophr Res 2002; 57: 139-46.
45. Catts VS, Catts SV, O'Toole BI, Frost ADJ. Cancer incidence in patients with schizophrenia and their first-degree relatives - a meta-analysis. Acta Psychiatr Scand 2008; 117: 323-36.
46. Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry 2011; 168: 1303-10.
47. Arnaiz A, Zumarraga M, Diez-Altuna I, Uriarte JJ, Moro J, Perez- Ansorena MA. Oral health and the symptoms of schizophrenia Psychiatry Res 2011; 188: 24-8.
48. Malhotra R, Kapoor A, Grover V, Kaushal S. Nicotine and periodontal tissues. J Indian Soc Periodontol 2010; 14: 72-9.
49. Eaton WW, Pedersen MG, Nielsen PR, Mortensen PB. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord 2010; 12: 638-46.
50. Gris JC, Brenner B. Antiphospholipid antibodies: neuropsychiatric presentations Semin Thromb Hemost 2013; 39: 935-42.
51. Delluc A, Rousseau A, Le Galudec M, et al. Prevalence of antiphospholipid antibodies in psychiatric patients, users and nonusers of antipsychotics. Br J Haematol 2014; 164: 272-9.
52. Krone KA, Allen KL, McCrae KR. Impaired fibrinolysis in the antiphospholipid syndrome. Curr Rheumat Rep 2010; 12: 53-7.
53. Danese S, Vetrano S, Zhang L, Poplis VA, Castellino FJ. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood 2010; 115: 1121-30.
54. van Zonneveld AJ, Curriden SA, Loskutoff DJ. Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. Proc Natl Acad Sci USA 1988; 85: 5525-9.
55. Guest PC, Wang L, Harris LW, et al. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol Psychiatry 2010; 15: 118-9.
56. Venkatasubramanian G, Chittiprol S, Neelakantachar N, et al. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 2007; 164: 1557-60.
57. Cohen D, Batstra MR, Gispen-de Wied CC. Immunological characteristics of diabetes in schizophrenia. Diabetologia 2005; 48: 1941-2.
58. McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia. Descriptive study. Br J Psychiatry 2003; 183: 534-9.
59. Correll CU, Robinson DG, Schooler NR, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders. Baseline results from the RAISE-ETP study. JAMA Psychiatry 2014; 71: 1350-63.
60. Baron AD. Insulin resistance and vascular function. J. Diabetes Complic 2002; 16: 92-102.
61. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006; 113: 1708-14.
62. Sironi AM, Sicari R, Folli F, Gastaldelli A. Ectopic fat storage, insulin resistance, and hypertension. Curr Pharm Des 2011; 17: 3074-80.
63. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome links, causes, and consequences. Arterioscl Thromb Vasc Biol 2006; 26: 2200-7.
64. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-8.
65. Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscl Thromb Vasc Biol 1998; 18: 20-6.
66. Isomaa BO, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.
67. Carvalho-Filho MA, Ueno M, Hirabara SM, et al. S-nitrosation of the insulin receptor, insulin receptor substrate 1, and protein Kinase B/Akt: A novel mechanism of insulin resistance. Diabetes 2005; 54: 959-67.
68. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995; 75: 473-86.
69. Arranz B, Rosel P, Ramirez N, et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 2004; 65: 1335-42.
70. Kale A, Naphade N, Sapkale S, et al. Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: Implications for altered one-carbon metabolism. Psychiatry Res 2010; 175: 47-53.
71. Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry 2006; 11: 143-9.
72. Hajjar K. Homocysteine: a sulph'rous fire. J Clin Invest 2001; 107: 663-4.
73. Goff DC, Bottiglieri T, Arning E, et al. Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry 2004; 161(9): 1705-8.
74. Miyashita M, Arai M, Kobori A, et al. Clinical features of schizophrenia with enhanced carbonyl stress. Schizophr Bull 2014; 40: 1040-6.
75. Blasco C, Caballeria J, Deulofeu R, et al. Prevalence and mechanisms of hyperhomocysteinemia in chronic alcoholics. Alcohol Clin Exp Res 2005; 29: 1044-8.
76. De Bree A, Verschuren WM, Kromhout D, Kluijtmans LA, Blom HJ. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev 2002; 54: 599-618.
77. Benowitz NL. Clinical pharmacology of caffeine. Ann Rev Med 1990; 41: 277-88.